Trading at 29% below its peak, Tesla now finds itself the object of cautious courtship rather than ardent pursuit. Let us, with due decorum, examine the merits of this union before determining whether such a match might prove advantageous to one’s portfolio.
If we are to speak of labyrinths, let us not ignore the smaller, more intricate ones. Consider Archer Aviation (ACHR), a company whose ambitions hover between the terrestrial and the celestial. Its eVTOL aircraft, the Midnight, is less a machine than a riddle posed to gravity. With eight pivoting motors and wings that whisper promises of speed, it is both helicopter and airplane-a creature stitched from the fabric of paradoxes.
Come, dear readers, let us embark on this delightful escapade, seeking the truths hidden beneath their soaring numbers. Are they to be cherished or cast aside like stale biscuits?
What say you, then? Should one buy into the grand spectacle that is Lucid Motors? Might we dare to dream that the company’s future will shimmer in the electric glow of progress? Let us examine, in the manner of any good play, two acts that might guide our decision.
They call it the crypto “killer app,” which sounds impressive until you realize it’s probably just another shiny thing to distract us all, while the risks and doubts quietly sip their tea in the corner.
The path is not one that demands the hurried, clumsy footfall of a speculative gambler. No, investing-true investing-is a methodical, almost artful pursuit. A choice which, over time, has proven itself as an irreplaceable means for the creation of wealth. And the avenue of exchange-traded funds (ETFs)-oh, how they stand, quiet, unassuming, yet filled with potential-is the epitome of such an art. They demand neither your constant attention nor your daily worries, while quietly curating a portfolio of stocks in their care. A masterpiece slowly but surely taking shape.
In this tale of two companies-Quantum Computing Inc. (QUBT), the upstart dreamer, and Nvidia (NVDA), the seasoned titan-we shall peel back the layers of hype and examine what lies beneath. Are these companies building castles in the sky, or do they offer tools that might one day lighten the burdens of the weary worker? Let us delve deeper, with clear eyes and skeptical hearts.
In case you were living under a rock (or, you know, genuinely enjoying your holiday), analyst Shane Brett from Morgan Stanley (NYSE: MS) made his big move over Labor Day: he downgraded Lam Research’s stock from “equalweight” (read: “hold, for now”) to “underweight” (aka “sell, ASAP”). All that optimism? Gone. With his decision, Brett also shaved off a couple of bucks from his price target, now sitting at $92 a share instead of $94. You can almost hear the sound of calculators tapping away in the background.
Canary Capital-imagine a bird that’s also a financial prophet-has chimed with predictions so audacious they might make a sardonic grin. Steven McClurg, that sharp-suited oracle of Finance Inc., proclaims XRP as the second most revered cryptocurrency on Wall Street, trailing only the venerable Bitcoin-because, naturally, everyone loves a little divisiveness. This recognition is no small feat; it signifies that institutional sharks prefer their assets familiar, like a well-worn cigar or a tasseled loafer.
Of the twin deals struck by Thermo Fisher, one stands out like a cryptic tome in a forgotten archive: the $4 billion acquisition of Solventum’s purification and filtration business. Solventum, once part of the industrial colossus 3M, now passes into the hands of Thermo Fisher through an all-cash transaction-a sum so vast it might have been plucked from the dreams of alchemists.